← Back to Clinical Trials
Recruiting NCT06802003

NCT06802003 Predicting Acute Exacerbations of COPD Using Wearable Devices and Remote Monitoring Technology With AI/ML Models

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06802003
Status Recruiting
Phase
Sponsor McGill University Health Centre/Research Institute of the McGill University Health Centre
Condition COPD
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-05-22
Primary Completion 2026-05-31

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age N/A
Study Type OBSERVATIONAL
All Conditions
Interventions
Biometric wearable and handheld devices

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-05-22 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is aimed to collect real-time physiological data using two wearable devices (a biometric ring and a biometric wristband), daily lung mechanical measurements by a handheld oscillometer, and participant-reported symptoms in patients with COPD remotely from their home environment. The data will be used to train and validate artificial intelligence and machine learning (AI/ML) models to predict COPD exacerbations in advance of their actual occurrence. The data will also be used to test the new severity classification system for exacerbations of COPD, as well as to determine important relationships between physiological measurements from the wearable devices, the handheld oscillometer, the self-reported symptoms, and the tests performed at the baseline visit.

Eligibility Criteria

Inclusion Criteria: * Males/females, age ≥ 40, former/current smokers with ≥10 pack-year smoking history * FEV1/FVC \< 0.7, with 80% \< FEV1 ≤50% (moderate, 'GOLD 2') 50% \< FEV1 ≤ 30% (severe, 'GOLD 3') or FEV1 \< 30% (very severe, 'GOLD 4') COPD * History of 2 or more exacerbations in the preceding 12 months requiring corticosteroids, antibiotics, or both * Ability to provide informed consent * Ability to access internet at least once daily Exclusion Criteria: * No existing COPD diagnosis * Any medical/cognitive/functional condition which renders inability to operate research equipment/devices, and/or to complete daily symptom response

Contact & Investigator

Central Contact

Bryan A. Ross, MD, MSc (Physiol), MSc (Epi)

✉ bryan.ross@mcgill.ca

📞 (514) 843-1465

Frequently Asked Questions

Who can join the NCT06802003 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, studying COPD. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06802003 currently recruiting?

Yes, NCT06802003 is actively recruiting participants. Contact the research team at bryan.ross@mcgill.ca for enrollment information.

Where is the NCT06802003 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT06802003 clinical trial?

NCT06802003 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology